April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Response to supplementation with lutein and zeaxanthin in subjects with familial history of AMD: the LIMPIA Study
Author Affiliations & Notes
  • Marie-Noelle Delyfer
    Ophthalmology, Hopital Pellegrin, Bordeaux, France
    Univ. Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France
  • Marie B Rougier
    Ophthalmology, Hopital Pellegrin, Bordeaux, France
  • Catherine P Garcher
    Service d’Ophtalmologie, CHU de Dijon, Dijon, France
  • Helene Savel
    Pôle de Santé Publique, Unité de soutien méthodologique à la recherche clinique et épidémiologie (USMR), CHU de Bordeaux, Bordeaux, France
  • Genevieve Chene
    Pôle de Santé Publique, Unité de soutien méthodologique à la recherche clinique et épidémiologie (USMR), CHU de Bordeaux, Bordeaux, France
  • Stéphane Etheve
    Research and Development, DSM Nutritional Products, Kaiseraugst, Switzerland
  • Wolfgang Schalch
    Research and Development, DSM Nutritional Products, Kaiseraugst, Switzerland
  • Cecile DelCourt
    Univ. Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France
    ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, INSERM, Bordeaux, France
  • Jean-Francois Korobelnik
    Ophthalmology, Hopital Pellegrin, Bordeaux, France
    Univ. Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France
  • Footnotes
    Commercial Relationships Marie-Noelle Delyfer, Alcon (C), Carl Zeiss Meditec. (C), Laboratoires Théa. (C), Novartis (C); Marie Rougier, Allergan (C), Bausch+Lomb (C), Kemin (C), Thea (C); Catherine Garcher, Alcon (C), Allergan (C), Bausch and Lomb (C), Bayer Pharma (C), Laboratoires Théa (C), Novartis (E); Helene Savel, None; Genevieve Chene, None; Stéphane Etheve, None; Wolfgang Schalch, None; Cecile DelCourt, Bausch&Lomb (C), Laboratoires Théa (C), Novartis (C); Jean-Francois Korobelnik, Alcon (C), Allergan (C), Bayer Pharma. (C), Carl Zeiss Meditec (C), Laboratoires Théa (C), Novartis (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1182. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marie-Noelle Delyfer, Marie B Rougier, Catherine P Garcher, Helene Savel, Genevieve Chene, Stéphane Etheve, Wolfgang Schalch, Cecile DelCourt, Jean-Francois Korobelnik; Response to supplementation with lutein and zeaxanthin in subjects with familial history of AMD: the LIMPIA Study. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1182.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To assess the effect of nutritional supplementation on plasma lutein and zeaxanthin in healthy subjects with familial history of AMD.

Methods: The Limpia Study is a randomized clinical trial performed in 120 healthy subjects aged 40-70 years with at least one parent affected by neovascular AMD. Included subjects were randomly assigned to receive Nutrof® Total (2 gels/day, representing lutein 10 mg/day, zeaxanthin 2 mg/day, long chain omega 3 fatty acids 540 mg/day, vitamin C 180 mg/day, vitamin E 30 mg/day, zinc 15 mg/day, copper 1 mg/day and resveratrol 1 mg/day) or placebo for 6 months, and were subsequently followed for 6 additional months after the end of supplementation. Plasma lutein and zeaxanthin were measured by normal-phase HPLC, from fasting blood samples.

Results: Baseline plasma lutein concentrations were 0.38 µmol/l ± 0.15 in the supplemented group and 0.37 µmol/l ± 0.16 in the placebo group. It increased in the supplemented subjects during the supplementation period (change from baseline +0.58 µmol/l ± 0.41 in the supplemented group and -0.02 µmol/l ± 0.09 in the placebo group at 3 months, p<0.0001 and +0.59 µmol/l ± 0.39 versus -0.04 ±0.12 at 6 months, p<0.0001). Three months after the end of supplementation, the supplemented group was still different from placebo (change from baseline +0.02± 0.10 versus -0.02 ± 0.12, p=0.03), but this difference between groups was no longer significant at 6 months (+0.01± 0.10 versus -0.02 ± 0.11, p=0.09). Baseline plasma zeaxanthin concentrations were 0.08 µmol/l ± 0.04 in the supplemented group and 0.09 ± 0.04 in the placebo group. It increased in the supplemented subjects during the supplementation period (change from baseline +0.14 ± 0.09 versus -0.01± 0.03, p<0.0001 at 3 months and +0.14 ± 0.09 versus -0.01± 0.03, p<0.0001 at 6 months), and, remained slightly higher after the end of supplementation (+0.01 ± 0.04 versus -0.01± 0.03, p=0.002, 3 months after the end of supplementation and +0.01 ± 0.03 versus -0.01± 0.03, p=0.003, 6 months after the end of supplementation).

Conclusions: This study documents an increase of more than 150% in plasma L and Z with Nutrof supplementation, in subjects at high genetic risk for AMD. A minimal difference in plasma L and Z between supplemented and placebo groups persisted several months after the end of supplementation.

Keywords: 412 age-related macular degeneration • 618 nutritional factors • 444 carotenoids/carotenoid binding proteins  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×